a potent and highly selective Btk inhibitor with IC50 of 0.5 nM .On November 13 2013 ,Pharmacyclis declared that USFDA approved Ibrutinib(Trade Mark IMBRUVICA) ,which is the
milstone commercial market explore .
We successfully synthesis its intermediate.
cas 330786-24-8 3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
cas 2215-77-2 4-Phenoxybenzoic
cas 143900-44-1 (S)-1-BOC-Piperidin-3-ol
cas 18107-18-1 Trimethyl(diazomethyl)silane
cas 51067-38-0 4-Phenoxybenzeneboronic acid
cas 2380-63-4 1H-Pyrazolo[3,4-d]pyrimidin-4-amine
cas 83255-86-0 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
activebiopharma
Joinhands Sci Park No.4028 Nanhuan RD Hangzhou ,310053 China
+86 (0) 13336028439
+86 (0)571 81612335
www.activebiopharma.com
